<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611766</url>
  </required_header>
  <id_info>
    <org_study_id>SGOG OV 2</org_study_id>
    <secondary_id>SGOG OV2</secondary_id>
    <nct_id>NCT01611766</nct_id>
  </id_info>
  <brief_title>Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?</brief_title>
  <official_title>Evaluation of Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase III, Multicenter, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Gynecologic Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the role of secondary cytoreduction (SCR) and&#xD;
      validate the risk model of patient selection criteria in platinum-sensitive recurrent ovarian&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to determine whether secondary cytoreduction followed by&#xD;
      chemotherapy is superior to chemotherapy alone in improving progression-free survival (PFS)&#xD;
      and overall survival (OS) in patients with platinum-sensitive recurrent ovarian cancer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 19, 2012</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 60 months after last patient randomized</time_frame>
    <description>from date of randomisation until death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 24 months after last patient randomized</time_frame>
    <description>interval between date of randomization and the date of second relapse/ progression or death, whatever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accumulating Treatment-free survival (TFSa)</measure>
    <time_frame>Up to 60 months after last patient randomized</time_frame>
    <description>the time of OS minus each treatment period after randomization, including surgery and chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival after the adjustment of one-way treatment switching</measure>
    <time_frame>Up to 60 months after last patient randomized</time_frame>
    <description>OS adjusted by statistical models for crossover</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day post-operative complications</measure>
    <time_frame>From the operation until after 30 days</time_frame>
    <description>MSKCC surgical complications grading method and CTCAE v4.03 criteria will be adopted for evaluating the perioperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Validation of iMODEL</measure>
    <time_frame>From randomization to operation</time_frame>
    <description>iMODEL score to predict complete resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient compliance</measure>
    <time_frame>Up to 60 months after last patient randomized</time_frame>
    <description>compliance with protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessments</measure>
    <time_frame>Study entry; 6 months; 12 months; 24 months and 60 months after randomization</time_frame>
    <description>The EORTC core quality of life questionnaire (QLQ-C30, version 3.0) Functional Assessment of Cancer Therapy- Ovary (FACT-O)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first subsequent anticancer therapy</measure>
    <time_frame>Up to 60 months after last patient randomized</time_frame>
    <description>From date of randomization until the date of first recurrent anticancer therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second subsequent anticancer therapy</measure>
    <time_frame>Up to 60 months after last patient randomized</time_frame>
    <description>From date of randomization until the date of secondary recurrent anticancer therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">356</enrollment>
  <condition>Ovarian Epithelial Cancer Recurrent</condition>
  <condition>Fallopian Tube Carcinoma</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>secondary cytoreductive surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SCR followed by chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salvage Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>platinum-based chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Secondary Cytoreductive Surgery</intervention_name>
    <description>Complete Cytoreduction</description>
    <arm_group_label>secondary cytoreductive surgery</arm_group_label>
    <other_name>Maximum effort cytoreductive surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salvage Chemotherapy</intervention_name>
    <description>6 cycles of postoperative chemotherapy</description>
    <arm_group_label>Salvage Chemotherapy</arm_group_label>
    <arm_group_label>secondary cytoreductive surgery</arm_group_label>
    <other_name>second line chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age at recurrence â‰¥ 18 years&#xD;
&#xD;
          -  Patients with platinum-sensitive, first relapsed epithelial ovarian, primary&#xD;
             peritoneal, or fallopian tube cancer (EOC, PPC, FTC), which is defined as those with&#xD;
             treatment -free interval of 6 months or more.&#xD;
&#xD;
          -  A complete secondary cytoreduction predicting score, iMODEL [Tian WJ, Ann Surg Oncol&#xD;
             2012,19(2):597-604]&lt;=4.7, including FIGO stage (0 or 0.8); residual disease after&#xD;
             primary surgery (0 or 1.5); Progression-free interval (0 or 2.4); PS ECOG (0 or 2.4);&#xD;
             Ca125 (0 or 1.8); and ascites at recurrence (0 or 3.0). If PI and CO-PI reach&#xD;
             consensus that the recurrent tumor detected by PET/CT could be completely resected,&#xD;
             the index of CA125 could be scored as 0. (Revised on 09/30/2013)&#xD;
&#xD;
          -  Assessed by the experienced surgeons, complete resection of all recurrent disease is&#xD;
             possible. If single lesion outside the peritoneal cavity can be resected, MRI/CT or&#xD;
             PET/CT scan should be performed to exclude simultaneous intra-abdominal lesions.&#xD;
&#xD;
          -  Patients who have given their signed and written informed consent and their consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with borderline tumors as well as non-epithelial tumors.&#xD;
&#xD;
          -  Patients for interval-debulking, or for second-look surgery, or palliative surgery&#xD;
             planned.&#xD;
&#xD;
          -  Impossible to assess the resectability or evaluate the score. Radiological signs&#xD;
             suggesting complete resection is impossible.&#xD;
&#xD;
          -  More than one prior chemotherapy.&#xD;
&#xD;
          -  Second relapse or more&#xD;
&#xD;
          -  Patients with second or other malignancies who have been treated by surgery, if the&#xD;
             treatment might interfere with the treatment of relapsed ovarian cancer or if major&#xD;
             impact on prognosis is expected.&#xD;
&#xD;
          -  Progression during chemotherapy or recurrence within 6 months after first-line therapy&#xD;
&#xD;
          -  Any contradiction not allowing surgery and/or chemotherapy&#xD;
&#xD;
               1. Accompanied by hypoxia serious chronic obstructive pulmonary disease&#xD;
&#xD;
               2. Uncontrolled hypertension, cerebrovascular accident/ Stroke, myocardial infarct,&#xD;
                  unstable angina, untreated thrombosis, chronic congestive heart failure, or&#xD;
                  serious arrhythmia in need of medicine.&#xD;
&#xD;
               3. Severe hepatitis, history of liver disease, nephrotic syndrome, renal&#xD;
                  insufficiency&#xD;
&#xD;
               4. Active ulcer history, abdominal wall fistula, perforation of gastrointestinal&#xD;
                  tract, or Intra-abdominal abscess, or simultaneously apply treatment/prevent&#xD;
                  ulcers therapy.&#xD;
&#xD;
               5. Uncontrolled diabetes&#xD;
&#xD;
               6. Uncontrolled epilepsy need long-term antiepileptic treatment.&#xD;
&#xD;
          -  Any medication induced considerable risk of surgery, e.g. estimated bleeding due to&#xD;
             oral anticoagulating agents, or bevacizumab.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rongyu Zang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ShanghaiGOG.org</url>
    <description>Shanghai Gynecologic Oncology Group</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>secondary cytoreductive surgery</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>surgery</keyword>
  <keyword>recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

